Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis

• DOI: 10.1016/j.ijid.2023.11.013
• Publication Date: 2023-11-28T17:01:34Z
• Authors: Anna-Maria Dittrich; Sarah Sieber; Lutz Naehrlich; Manuel Burkhart; Sylvia Hafkemeyer; Burkhard Tümmler
• Keywords: Ivacaftor

ObjectivesThe impressive improvements of CFTR function by elexacaftor/tezacaftor/ivacaftor (ETI) result in changes the detection frequencies Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA). We assessed determinants response to ETI with regards SA PA as documented German CF Registry for people (pwCF) ≥12 years.MethodsWe evaluated 21 months before after initiation used different statistical tests identify changes.ResultsWe included data from 1,092 pwCF results culture-dependent diagnostics 7,944 microbiological samples prior 6.845 ETI. Detections decreased 54.3% 44.3% 40.2% those 39.9% 31.9% 22.6% 3 therapy, respectively (all p<0.001). Reduction were observed throat swabs sputa, associated significantly age, lung dependent on pre-ETI colonization status.ConclusionsThe patterns reductions suggest that pathogen-specific biological processes govern responsiveness towards pwCF.